Nelly

@NocturnalNelly • 6,786 subscribers

performance pharmacology

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

Bromantane seminar: scuffed high-level overview

Bromantane seminar: scuffed high-level overview

20,199 次观看 • 3 天前

ATX-304: the shitty high level seminar overview > how it works > what it might do > side effects seen > protocol considerations > whether it’s even worth giving a shit about not a to z. this drug is a fucking biochemical hostage situation. there will be many questions. please ask away, lol.

ATX-304: the shitty high level seminar overview > how it works > what it might do > side effects seen > protocol considerations > whether it’s even worth giving a shit about not a to z. this drug is a fucking biochemical hostage situation. there will be many questions. please ask away, lol.

14,006 次观看 • 9 天前

What in the actual fuck are SLU-PP-332 and SLU-PP-915 doing inside of a cell to jack up sustained endurance capacity? "Quick" + "simple" breakdown + incoherent anecdotal rambling:

What in the actual fuck are SLU-PP-332 and SLU-PP-915 doing inside of a cell to jack up sustained endurance capacity? "Quick" + "simple" breakdown + incoherent anecdotal rambling:

20,050 次观看 • 20 天前

If you pin IM and your quads / delts / glutes fucking hate you - Allow me to introduce you to the secret Lat pinning sauce:

If you pin IM and your quads / delts / glutes fucking hate you - Allow me to introduce you to the secret Lat pinning sauce:

11,457 次观看 • 17 天前

This one is potentially very interesting for the TRT guys. There's a new peptide approaching an FDA decision called Rusfertide. It lowers Hematocrit. In the Phase 3 VERIFY trial in 293 patients with Polycythemia Vera, 76.9% of patients receiving Rusfertide achieved the primary clinical response versus 32.9% with placebo. 62.6% maintained hematocrit <45% through 32 weeks versus 14.4% with placebo, and patients averaged 0.5 phlebotomies versus 1.8. Important: This has been studied in polycythemia vera, not the TRT goon squad (us) taking Test and jacking up their HCT. I'll be paying very close attention. This is how it works:

This one is potentially very interesting for the TRT guys. There's a new peptide approaching an FDA decision called Rusfertide. It lowers Hematocrit. In the Phase 3 VERIFY trial in 293 patients with Polycythemia Vera, 76.9% of patients receiving Rusfertide achieved the primary clinical response versus 32.9% with placebo. 62.6% maintained hematocrit <45% through 32 weeks versus 14.4% with placebo, and patients averaged 0.5 phlebotomies versus 1.8. Important: This has been studied in polycythemia vera, not the TRT goon squad (us) taking Test and jacking up their HCT. I'll be paying very close attention. This is how it works:

13,146 次观看 • 22 天前

没有更多内容可加载